DB旗舰

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF PENPULIMAB INJECTION BY THE US FDA

VOLUNTARY ANNOUNCEMENT - 45 RESEARCH RESULTS WILL BE PRESENTED AT 2025 ASCO ANNUAL MEETING (INCLUDING 12 ORAL SESSIONS)

ADOPTION OF THE NEW ARTICLES

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB3019 (BTK PROTAC)" APPROVED BY NMPA

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB6411 (EGFR/C-MET BISPECIFIC ADC)"ACCEPTED BY CDE

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB2101 (ROR1 ADC)" APPROVED BY NMPA